Halofantrine
Clinical data | |
---|---|
Trade names | Halfan |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a603030 |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Protein binding | 60–70% |
Metabolism | Hepatic (CYP3A4-mediated) |
Elimination half-life | 6–10 days |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Halofantrine is a drug used to treat
Halofantrine was developed at SRI International for the Walter Reed Army Institute of Research from 1965 to 1975 by a team led by medicinal chemist William Colwell.[3]
Adverse reactions
Halofantrine can cause abdominal pain,
It can be associated with
Other adverse reactions
Consumption of grapefruit combined with certain medications can cause serious side effects, even death. Halofantrine combined with this fruit or grapefruit juice is dangerous. The mechanism of action is inhibition of CYP3A4, which is necessary to metabolize the drug and eliminate it from the body. Without CYP3A4, levels of the drug will become toxic in the body.
Pharmacology
The mechanism of action of halofantrine is unknown. The absorption of halofantrine is erratic, but is increased when taken with fatty food. Because of fears of toxicity due to increased halofantrine blood levels, halofantrine should be taken on an empty stomach.
Plasma levels peak at 16 hours and the half-life of the drug is about 4 days.
Uses
Halofantrine is only used to treat malaria. It is not used to prevent malaria (
Dosing
Adult dose: three doses of 500 mg six hours apart. Halofantrine should be taken on an empty stomach.
Manufacturing information and availability
Halfan (
References
- PMID 18508124.
- S2CID 14642593. Archived from the original(PDF) on 2020-08-07. Retrieved 2019-04-08.
- ISBN 978-0974520810.
- S2CID 23780132.
- S2CID 1948028.
- PMID 20003315.